News
-
-
PRESS RELEASE
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
Onco-Innovations announces commencement of manufacturing for preclinical testing of nanoparticle-formulated PNKP inhibitor technology in collaboration with Dalton Pharma Services -
-
-
-
PRESS RELEASE
Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology
Onco-Innovations appoints Professor Steven Jones as Senior Scientific Advisor to advance precision oncology through AI-powered solutions -
-
PRESS RELEASE
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
Onco-Innovations Limited to transfer listing of Common Shares to Cboe Canada from CSE; trading on Cboe Canada begins on May 22, 2025. Company aims for investor trust, liquidity, and visibility under existing ticker symbol 'ONCO' -
-
PRESS RELEASE
Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science
Onco-Innovations Limited's subsidiary, Inka Health Corp., partners with AstraZeneca Canada for real-world evidence research in oncology. The new engagement showcases Inka Health's expertise in evidence translation and market access